Navigation Links
Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
Date:5/3/2012

ure to dabigatran. Concomitant use of P-gp inhibitors in patients with renal impairment is expected to increase exposure of dabigatran compared to either factor alone.

  • For patients with moderate renal impairment (CrCl 30-50 mL/min), consider reducing the dose of PRADAXA to 75 mg twice daily when dronedarone or systemic ketoconazole is coadministered with PRADAXA.
  • For patients with severe renal impairment (CrCl 15-30 mL/min), avoid concomitant use of PRADAXA and P-gp inhibitors.

ADVERSE REACTIONS

In the pivotal trial comparing PRADAXA to warfarin, the most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal (GI) events. PRADAXA 150 mg resulted in a higher rate of major GI bleeds and any GI bleeds compared to warfarin. In patients ≥75 years of age, the risk of major bleeding may be greater with PRADAXA than with warfarin. Patients on PRADAXA 150 mg had an increased incidence of GI adverse reactions. These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and GI ulcer). Drug hypersensitivity reactions were reported in <0.1% of patients receiving PRADAXA.

OTHER MEASURES EVALUATED

The risk of myocardial infarction was numerically greater in patients who received PRADAXA 150 mg than in those who received warfarin.

For full PRADAXA prescribing information, please visit www.pradaxa.com or contact Boehringer Ingelheim's Drug Information Unit at 1-800-542-6257.

About the Boehringer Ingelheim Cares Foundation Patient Assistance Programs

For more than 125 years, Boehringer Ingelheim has been focused on improving the lives of patients
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 /PRNewswire-iReach/ -- ChemImage announced today ... improvements in the development of imaging technology ... normal and diseased tissue that minimizes the ... procedures, lowers surgical costs and potentially enhances ... The clinical and scientific teams ...
(Date:9/17/2014)... 17, 2014 Prostate Oncology Specialists announces ... to educate men about new imaging technology destined ... prostate. Annually, a million men undergo random needle ... MRI (MP-MRI) of the prostate gland is non-invasive ... need to be fully informed of their alternatives. ...
(Date:9/17/2014)... , Sept. 17, 2014  Rebiotix Inc. announced this morning ... lead product candidate, RBX2660 (microbiota suspension) will be presented in ... conference in Philadelphia from October 8-12. ... during the poster session on Thursday, October 9, 2014: ... Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 ...
Breaking Medicine Technology:Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4
... ... ... ... ...
... , ... ... ... ...
Cached Medicine Technology:American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 2American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 3American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 4American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 5American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 6American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 7Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date 2Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date 3Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date 4
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- Social networking ... new study. For people who are obese, sites ... convenient source of support from doctors as well as ... media over other methods is that it offers the ... for day-to-day use when compared to traditional approaches," the ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 In Pretrial ... that “bi-weekly telephonic discovery conferences would be beneficial in ... conferences through mid-December. “At the end of December,” the ... the need for additional conferences. , “The plain ... that there is still much to be discussed as ...
(Date:9/17/2014)... Sept. 17, 2014 (HealthDay News) -- Positive messages about ... people kick the habit, a new study suggests. ... better to "loss-framed" messages about the harmful effects of ... whenever they want benefit more from "gain-framed," or positive, ... The researchers concluded that using a mix of both ...
(Date:9/17/2014)... 2014 Many countries choose to kill ... immunizations. The total number of poultry exceeds 10 billion ... will result in huge losses. Therefore, it is quite ... , Avian influenza vaccines have been used for more ... China began to use H5N1 avian influenza vaccines voluntarily ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 StartX ... revealed 12 companies raising rounds of funding at its ... few hundred investors and media, was the first such ... located next to the university. The presentations were delivered ... adjacent to StartX-QB3 Labs, a 2,000 square foot life ...
Breaking Medicine News(10 mins):Health News:Social Networking Sites Can Help Obese Lose Weight: Study 2Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6
... Campath, CAMBRIDGE, Mass. and WAYNE, N.J., Sept. ... Bayer HealthCare Pharmaceuticals Inc.,(NYSE: BAY ) today ... has approved a supplemental biologics license application (sBLA) ... for the treatment of B-cell chronic lymphocytic leukemia ...
... LLC, today announced the,U.S. Food and Drug Administration ... use in intervertebral fusion procedures.,Included are versions to ... without the need for supplemental fixation. Fusion ... performed by,neurosurgeons and orthopedic spine surgeons. The InterPlate ...
... Cephalon, Inc. (Nasdaq:,CEPH) today announced that it has ... Food and Drug Administration (FDA) requesting approval of,TREANDA(R) ... chronic,lymphocytic leukemia (CLL). CLL is a slowly progressing ... new cases diagnosed every year in,the United States, ...
... new implant for marketing, NEW YORK, Sept. 21 ... products, technology and education for the,small bone and joint ... Spacer has been cleared by the FDA for marketing ... of surgically implanted, degradable,spacers to four applications with two ...
... you eat the right grains for breakfast, such as ... sugar is facilitated after breakfast, lunch, and dinner. It ... this effect all day. This is due to a ... of indigestible carbohydrates that occur in certain grain products. ...
... Aviv Universitys Sackler School of Medicine is, quite simply, a ... of a small number of surgeons in the world who ... has developed a novel laser device that promises to revolutionize ... now, is expected to give most practicing eye surgeons the ...
Cached Medicine News:Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 2Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 3Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 4Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 5Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 6Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 2Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 3Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 4Health News:Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 2Health News:Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 3Health News:Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 4Health News:Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 5Health News:Right breakfast bread keeps blood sugar in check all day 2Health News:Glaucoma surgery in the blink of an eye 2
Inquire...
... The Trinity Biotech Captia™ Mumps IgG ... the detection and quantitative determination of IgG ... Individual serum specimens may be used for ... acute and convalescent, may be used to ...
... AUTOMATION, INC. (DAI) Mumps IgG ... intended for the detection and ... to Mumps virus in human ... be used for the determination ...
... Corporation announced the launch of the ... first bi-directional cooled-tip catheter available in the ... offers physicians the benefits of cooled ablation ... the Boston Scientific Blazer(R) catheter platform. ,Cooled ...
Medicine Products: